Drug Profile
Adezmapimod - GSK
Alternative Names: BIRB-203580; PB-203580; RWJ 64809; SB-203580Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; University of Cambridge
- Class Anti-inflammatories; Antirheumatics; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Postmenopausal osteoporosis; Rheumatoid arthritis; Septic shock